NCT05257551招募中不适用
TEMPUS SCLC OBSERVATIONAL STUDY: A Tissue and Longitudinal Circulating Tumor DNA (ctDNA) Biomarker Profiling Study of Patients With Small Cell Lung Cancer (SCLC) Using Comprehensive Next-Generation Sequencing (NGS) Assays
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- Tempus AI
- 入组人数
- 200
- 试验地点
- 11
- 主要终点
- To determine if tumor tissue transcriptional subtypes can be detected
研究概览
简要总结
The study is a non-interventional evaluation of participants with extensive stage (ES) SCLC who will receive diagnostic and (where possible) post-progression tumor tissue profiling, alongside plasma ctDNA and CTC biomarker profiling during standard of care therapy in both first and second line treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •. Participants are eligible to be included in this study only if all the following criteria apply. The participant has/is:
- •Histologically confirmed small cell lung cancer diagnosis
- •Diagnosis made with excisional or core needle biopsy specimen (fine needle aspirate may be permitted with approval from the Medical Monitor)
- •Subjects must submit tumor sample per the laboratory manual, defined as follows: 1L Cohort - Tissue obtained prior to the initiation of 1L therapy; 2L Cohort - Tissue obtained prior to the initiation of 1L therapy and/or a standard of care re-biopsy prior to the start of 2L therapy, if performed.
- •ECOG performance status of 0-2 at time of enrollment
- •For participants entering prior to first line therapy, planned extensive stage first-line therapy of etoposide plus platinum plus PD-L1 inhibitor (atezolizumab or durvalumab)
- •For participants entering post completion of standard of care first line prior to second line therapy, completion of an EP+CPI with or without maintenance therapy. Note: Participants who received 1L therapy that is not standard of care i.e., investigational therapy, are not eligible.
- •Extensive stage disease at time of diagnosis according to NCCN definition: Extensive Stage Small Cell Lung Cancer (SCLC) as either Stage IV disease (any T, any N, with M1a/b/c) or T3-4 disease due to multiple lung nodules that are too extensive or have a tumor/nodal volume that is too large to be encompassed in a tolerable radiation plan (NCCN version 2.2026-September 16, 2025).
- •Willing and able to provide informed consent
- •Palliative radiotherapy is permitted as long as there is measurable disease outside of the radiotherapy port with which to assess response to therapy delivered
- •Participants will be excluded from the study if any of the following criteria apply. The participant has/is:
- •Patients with a secondary malignancy must have been both diagnosed > 3 years from the lung cancer of interest and have completed all therapy for that malignancy > 3 years prior to diagnosis of the lung cancer of interest, with the exception of the following:
- •Patients with superficial basal cell carcinoma of low-risk histology per NCCN Guidelines (Low-risk histologic subtypes include nodular, superficial, and other non-aggressive growth patterns such as keratotic, infundibulocystic, and fibroepithelioma of Pinkus) and low-risk for recurrence per NCCN Guidelines (location on trunk or extremities, size < 2 cm, primary (not recurrent), with well-defined borders) can be included even if they are diagnosed < 3 years from the lung cancer of interest.
- •Patients with superficial squamous cell carcinoma of low-risk pathology per NCCN Guidelines (verrucous, keratoacanthomatous) and low-risk for recurrence per NCCN Guidelines (located on trunk or extremities; ≤ 2 cm in size; primary lesion (vs. recurrent); well to moderately differentiated; < 2 mm thick and no invasion beyond subcutaneous fat; negative for perineural invasion; and negative for lymphatic or vascular involvement) can be included even if they are diagnosed < 3 years from the lung cancer of interest.
- •Mixed small cell and non-small cell histology
- •Small cell cancers of origin in other organs or suspected metastatic cancer from other sites (i.e., those without a known or suspected lung primary diagnosis)
- •Large Cell Neuroendocrine cancers
- •Carcinoids or atypical carcinoid tumors
- •Transformed small cell lung cancer emerging in the setting of targeted therapy for NSCLC
- •Treated with an investigational agent of another immunotherapy class (i.e., non PD-1 or PD-L1 inhibitor)
- •Not willing to have additional blood samples collected
排除标准
- 未提供
研究组 & 干预措施
Patients with Extensive Stage (ES) Small Cell Lung Cancer (SCLC)
This protocol will include participants with extensive stage small cell lung cancer receiving standard of care therapy in first and second line with tissue collected from the primary lung tumor or metastatic sites.
干预措施: Observation (Other)
结局指标
主要结局
To determine if tumor tissue transcriptional subtypes can be detected
时间窗: Up to 4 years
To determine prospectively if SCLC tumor tissue transcriptional subtypes can be detected by RNAseq
To characterize relationship between tissue transcriptional subtype and clinical outcomes
时间窗: Up to 4 years
To characterize the relationship between tissue transcriptional subtype and clinical outcomes for first and second line based on collection of longitudinal information from medical records
次要结局
- To test which tissue and sample variables confound gene expression subtypes(Up to 4 years)
- To assess the potential for liquid biopsy in SCLC(Up to 4 years)
- To characterize the relationship between longitudinal ctDNA methylation and CTC results with clinical outcomes for first and second line therapy based on collection of longitudinal information from medical records(Up to 4 years)
- To evaluate the relationship between initial molecular SCLC subtypes (e.g., SCLC-A, SCLC-N, SCLC-I) and the subsequent development of therapeutic resistance(Up to 4 years)
研究者
研究点 (11)
Loading locations...
相似试验
招募中
不适用
An Observational Study to Assess the Effectiveness and Safety of a Cemiplimab in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) in Routine Clinical Practice Settings in EuropeNon-small Cell Lung CancerNCT05363319Regeneron Pharmaceuticals500
招募中
不适用
18F-FDG PET/CT to Evaluate pD-1 Monoclonal Antibody With First-line Chemotherapy in Advanced NSCLCNSCLCNCT04996927Wuhan Union Hospital, China50
Unknown
不适用
A Study to Explore Treatment Regimens and Clinical Outcomes of the NSCLC Patients With Different Dirver GenesNon-small Cell Lung CancerNCT03710629The First Affiliated Hospital of Guangzhou Medical University750
已完成
不适用
A Study To Monitor Lung Cancer Patients Activity And Assess Performance Status Through A Wearable Device.Non-Small Cell Lung Cancer (NSCLC)NCT04751162Hoffmann-La Roche71
终止
1 期
Grapiprant (ARY-007) and Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 NSCLC AdenocarcinomaNon-small Cell Lung Cancer AdenocarcinomaNCT03696212Arrys Therapeutics18